Changeflow GovPing Pharma & Drug Safety IL-10 Muteins Patent - University of Dundee et al
Routine Notice Added Final

IL-10 Muteins Patent - University of Dundee et al

Favicon for changeflow.com EPO Patent Bulletin - Peptides (C07K)
Published
Detected
Email

Summary

The EPO granted patent EP4118104A1 to University of Dundee and co-applicants INSERM, Université de Lille, and CHRU Lille covering IL-10 muteins (modified cytokine variants), with protection extending across 31 designated European states. The patent covers modified interleukin-10 proteins with enhanced anti-inflammatory and immunomodulatory properties for potential therapeutic applications.

What changed

The EPO published patent application EP4118104A1 for IL-10 muteins (modified interleukin-10 cytokines), granted to University of Dundee and co-applicants INSERM, Université de Lille, and CHRU de Lille. The designated states include all 27 EU member states plus Switzerland, Norway, Iceland, Turkey, and other European states.

Academic research institutions and biotech or pharmaceutical companies developing interleukin-10 related therapeutics, anti-inflammatory drugs, or immunomodulatory treatments should assess potential patent infringement risks and licensing requirements. Freedom-to-operate analyses for any products in these therapeutic areas will need to account for this granted European patent.

What to do next

  1. Monitor for updates on patent enforcement activities
  2. Assess freedom-to-operate for related therapeutic development
  3. Evaluate licensing opportunities if developing competing IL-10 variants

Archived snapshot

Apr 10, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← EPO Patent Bulletin

IL-10 MUTEINS

Publication EP4118104A1 Kind: A1 Apr 01, 2026

Applicants

University of Dundee, Institut National de la Santé et de la
Recherche Médicale (INSERM), Université de Lille, CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE DE LILLE

Inventors

GORBY, Claire, GONZALEZ, Ignacio Moraga, MITRA, Suman

IPC Classifications

C07K 14/52 20060101AFI20210917BHEP

Designated States

AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR

View original document →

Get daily alerts for EPO Patent Bulletin - Peptides (C07K)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from EPO.

What's AI-generated?

The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.

Last updated

Classification

Agency
EPO
Published
April 1st, 2026
Instrument
Notice
Legal weight
Binding
Stage
Final
Change scope
Minor
Document ID
EP4118104A1

Who this affects

Applies to
Educational institutions Pharmaceutical companies Healthcare providers
Industry sector
3254.1 Biotechnology
Activity scope
Patent examination IP licensing Research and development
Geographic scope
European Union EU

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Pharmaceuticals Healthcare Biotechnology

Get alerts for this source

We'll email you when EPO Patent Bulletin - Peptides (C07K) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!